AI-driven healthcare company

Saving Lives by Detecting Cancer Early

Helio Genomics is on a mission to make cancer detection simple, affordable, and early — when it is most treatable. With just a blood draw, we are helping more people find cancer at the stage they are most likely to beat it.

Explore Our Platform → Discover HelioLiver →

Validated in the CLiMB Trial Published in the Journal of Hepatology Available through Quest Diagnostics

A joyful woman in her late fifties laughing during a sunlit morning walk in the park

Our Mission

Finding Cancer Early Is the Key to Beating It

For the majority of cancers, 90% of people survive when the disease is detected at an early stage. Yet too many of today’s diagnostics are inconvenient, expensive, and poor at catching cancer early, so too many people are diagnosed when it is already too late. Helio Genomics exists to change that. We focus our work on early detection, when treatment is most effective, and the chances of beating cancer are highest. By transforming how the world screens for cancer, we are working to give everyone the best possible chance.

survival rate when cancer is detected at an early stage, for the majority of cancers¹

The Platform

One Platform. A Smarter Way to Detect Cancer.

At the heart of Helio Genomics is a multi-analyte, blood-based platform that uses artificial intelligence to read the molecular signals of cancer. It is built to do more than find one disease; it is designed to change how cancer is detected and monitored across the entire patient journey.

Early Detection

We identify proprietary DNA methylation signatures that can reveal cancer as early as Stage I, from a single blood draw — when treatment works best.

Disease Monitoring

Beyond detection, our platform is designed to monitor minimal residual disease, helping clinicians track response and make informed decisions over time.

Powered by AI

Machine learning turns complex biomarker data into clear, reliable answers — built on proprietary, patented science developed over nearly a decade.

Explore the Technology →

Our First Commercial Test

HelioLiver™ LDT — Our Platform, Proven in the Clinic

HelioLiver LDT is the first test built on the Helio platform, and it is available for clinical use today. It is a simple blood test for the early detection of hepatocellular carcinoma (HCC), the most common form of liver cancer. In the CLiMB trial, HelioLiver detected Stage I liver cancer four times more often than ultrasound, the current standard of care.²

44% vs 11%Stage I HCC detection, HelioLiver vs ultrasound

29% vs 0%Sensitivity for lesions under 2 cm

10–14 daysAverage turnaround time

Validated in the CLiMB trial and published in the Journal of Hepatology, May 2026.

Discover HelioLiver LDT → For Healthcare Providers →

A clinician holding the HelioLiver blood collection kit

Science & Proof

Backed by Nearly a Decade of Peer-Reviewed Science

Since 2016, Helio Genomics has pioneered the use of DNA methylation for early cancer detection — with foundational research published in some of the world’s most respected scientific journals.

Read Our Research →

A scientist pipetting samples in a modern genomics laboratory

2016

Founded with a proprietary, patented methylation profile of novel cancer biomarkers.

2017

Early methylation detection research published in Nature and PNAS.

2021

An AI and machine-learning detection method published in Nature Communications.

2026

CLiMB trial results published in the Journal of Hepatology.

An older patient in a reassuring consultation with a physician

Why It Matters

Why Early Detection Changes Everything

When cancer is caught early, while it is still localised, survival rates are dramatically higher, and far more treatment options are available. Closing the gap between late and early diagnosis — across cancers, beginning with liver — is the heart of what we do.

37%

Early-stage (localised)

Five-year survival, liver cancer

Advanced-stage (distant)

Five-year survival, liver cancer

Five-year survival falls sharply from early-stage to advanced-stage liver cancer. Source: SEER Database.³

Learn About Early Detection →

Partners & Recognition

We Collaborate with Leaders in Clinical Care

Bringing groundbreaking cancer detection to patients takes partnership. Helio Genomics works alongside leading healthcare and technology organisations to expand access to early testing — including a strategic commercial partnership with Syneos Health and clinical availability through Quest Diagnostics.